World Of News

Brazil’s famously-tricky real estate market has long drawn international investors to the region in search of tech solutions. This time, Brazilian startup Loft brought in a $175M Series C from first-time investor in the region, Vulcan Capital (Paul Allen’s investment arm), alongside Andreessen Horowitz. Loft is also a16z’s first and only Brazilian investment.  Co-founded by serial entrepreneurs and investors, Mate Pencz and Florian Hagenbuch in 2018, Loft uses a proprietary algorithm to process transaction data and provide more transparent pricing for both buyers and sellers. The startup uses two models to help clients sell properties; either Loft will value the apartment for listing on the site, or they will offer to purchase the property from the buyer immediately. Many real estate platforms in the US are shifting toward a similar iBuyer model; however, this system may be even more apt for the Latin American market, where property sales are notoriously untransparent, bureaucratic

Legacy , a male fertility startup, has just raised a fresh, $3.5 million in funding from Bill Maris’s San Diego-based venture firm, Section 32, along with Y Combinator and Bain Capital Ventures, which led a $1.5 million seed round for the Boston startup last year. We talked earlier today with Legacy’s founder and CEO Khaled Kteily about his now two-year-old, five-person startup and its big ambitions to become the world’s preeminent male fertility center. Our biggest question was how Legacy and similar startups convince men — who are generally less concerned with their fertility than women — that they need the company’s at-home testing kits and services in the first place. “They should be worried about [their fertility],” said Kteily, a former healthcare and life sciences consultant with a masters degree in public policy from the Harvard Kennedy School. “Sperm counts have gone down 50 to 60 percent over the last 40 years.” More from our chat with Legacy, a former TechCrunch Battle

Ann Miura-Ko Contributor Share on Twitter Ann Miura-Ko is a co-founding partner at Floodgate , a seed-stage VC firm. A repeat member of the Forbes Midas List and the New York Times Top 20 Venture Capitalists Worldwide, she earned a PhD in math modeling of cybersecurity at Stanford University. Hi, I’m Ann . I was one of the first investors in Lyft, Refinery29 and Xamarin. I’ve been on the Midas List for the past three years and was recently named on The New York Times’ list of The Top 20 Venture Capitalists. In 2008, I co-founded Floodgate , one of the first seed-stage VC funds in Silicon Valley. Unlike most funds, we invest exclusively in seed, making us experts in finding product-market fit and building a minimum viable company. Seed is fundamentally different from later stages, so we’ve made it more than a specialty: It’s all we do. Each of our partners sees thousands of companies every year before electing to invest in only the top three or four. For the past 11 years

Ann Miura-Ko Contributor Share on Twitter Ann Miura-Ko is a co-founding partner at Floodgate , a seed-stage VC firm. A repeat member of the Forbes Midas List and the New York Times Top 20 Venture Capitalists Worldwide, she earned a PhD in math modeling of cybersecurity at Stanford University. Hi, I’m Ann . I was one of the first investors in Lyft, Refinery29 and Xamarin. I’ve been on the Midas List for the past three years and was recently named on The New York Times’ list of The Top 20 Venture Capitalists. In 2008, I co-founded Floodgate , one of the first seed-stage VC funds in Silicon Valley. Unlike most funds, we invest exclusively in seed, making us experts in finding product-market fit and building a minimum viable company. Seed is fundamentally different from later stages, so we’ve made it more than a specialty: It’s all we do. Each of our partners sees thousands of companies every year before electing to invest in only the top three or four. For the past 11 years

More than a year and a half after wireless carriers were caught red-handed selling the real-time location data of their customers to anyone willing to pay for it, the FCC has determined that they committed a crime. An official documentation of exactly how these companies violated the law is forthcoming. FCC Chairman Ajit Pai shared his finding in a letter to Congressman Frank Pallone (D-NJ), who chairs the Energy and Commerce Committee that oversees the agency. Rep. Pallone has been active on this and prodded the FCC for updates late last year, prompting today’s letter. (I expect a comment from his office shortly and will add it when they respond.) “I wish to inform you that the FCC’s Enforcement Bureau has completed its extensive investigation and that it has concluded that one or more wireless carriers apparently violated federal law,” Pai wrote. Extensive it must have been, since we first heard of this egregious breach of privacy in May of 2018, when multiple reports showed tha

There’s a reason why Data Privacy Day pisses me off. January 28 was the annual “Hallmark holiday” for cybersecurity, ostensibly a day devoted to promoting data privacy awareness and staying safe online. This year, as in recent years, it has become a launching pad for marketing fluff and promoting privacy practices that don’t hold up. Privacy has become a major component of our wider views on security, and it’s in sharper focus than ever as we see multiple examples of companies that harvest too much of our data, share it with others, sell it to advertisers and third parties and use it to track our every move so they can squeeze out a few more dollars. But as we become more aware of these issues, companies large and small clamor for attention about how their privacy practices are good for users. All too often, companies make hollow promises and empty claims that look fancy and meaningful.

Shares of One Medical are worth $19.50 this morning after the venture-backed unicorn priced its IPO at $14 per share last night . The company opened at $18 before rising further, according to Yahoo Finance data. At its current price, One Medical is worth about 40% more than its IPO price, a strong debut for the company. The result is a boon for One Medical, which raised $532.1 million during its time as a private company. At $14 per share, the company was worth $1.71 billion. At 19.50, One Medical is worth $2.38 billion, a winning result for a company said to be worth around $1.5 billion as a private company. For investors The Carlyle Group, J.P. Morgan, Redmile Group, GV and Benchmark (among others), the debut is a success, pricing their stakes in the company higher once again. For other unicorns, the news is even better. One Medical, a company with gross margins under the 50% mark, deeply minority recurring revenue and 30% revenue growth in 2019 at best is now worth about 8.5x i